Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | VEGFA | P15692 | 1/20 | 0.45 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.45 |
| ▸ | QPCT | Q16769 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | AKT2 | P31751 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SOD1 | P00441 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14416010 | 0.82 | SMN1; SMN2 (0.56) | CYP19A1VEGFAEGLN1QPCTSMN1; SMN2 | |
| SCHEMBL14416007 | 0.82 | CYP11B1 (0.60) | CYP19A1VEGFAEGLN1QPCTSMN1; SMN2 | |
| SCHEMBL3181153 | 0.82 | SMN1; SMN2 (0.57) | CYP19A1VEGFAEGLN1QPCTSMN1; SMN2 | |
| SCHEMBL21591530 | 0.81 | QPCT (0.51) | CYP19A1QPCTDRD4MEN1KMT2A | |
| SCHEMBL14416009 | 0.81 | CYP19A1 (0.67) | CYP19A1QPCTSMN1; SMN2POLBMAPK1 | |
| SCHEMBL2475754 | 0.78 | QPCT (0.67) | CYP19A1VEGFAEGLN1QPCTSMN1; SMN2 | |
| SCHEMBL8444490 | 0.78 | ALOX15 (0.60) | VEGFAEGLN1QPCTALDH1A1 | |
| SCHEMBL14416012 | 0.77 | VEGFA (0.55) | VEGFAEGLN1QPCTSMN1; SMN2MEN1 | |
| SCHEMBL14492302 | 0.77 | CYP11B1 (0.60) | VEGFAEGLN1QPCTSMN1; SMN2DRD4 | |
| SCHEMBL17572351 | 0.77 | CYP11B1 (0.60) | VEGFAEGLN1QPCTSMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162863-B2 | Modulators of stimulator of interferon genes (STING) | Ryvu Therapeutics S.A. (PL) | 2024-12-10 | — | — | US | disclosed |
| US-20220402898-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2022-12-22 | — | — | US | disclosed |
| US-20220402898-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2022-12-22 | — | — | US | disclosed |
| WO-2019238786-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2019-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12162863-B2 | Modulators of stimulator of interferon genes (STING) | STING1, IRF3, CGAS | CYP19A1 589/4885VEGFA 3195/4885EGLN1 3370/4885 |
| US-20220402898-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | STING1, IRF3, CGAS | CYP19A1 589/4885VEGFA 3195/4885EGLN1 3370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.